These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 19229289

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL.
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [Abstract] [Full Text] [Related]

  • 4. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
    Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N, Kirn D.
    Nat Biotechnol; 2003 Nov; 21(11):1328-35. PubMed ID: 14555956
    [Abstract] [Full Text] [Related]

  • 5. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo.
    Schowalter DB, Tubb JC, Liu M, Wilson CB, Kay MA.
    Gene Ther; 1997 Apr; 4(4):351-60. PubMed ID: 9176522
    [Abstract] [Full Text] [Related]

  • 6. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene.
    Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y, Cui Q, Liu L, Cai R, Qian C.
    Clin Cancer Res; 2008 Apr 15; 14(8):2450-7. PubMed ID: 18413837
    [Abstract] [Full Text] [Related]

  • 7. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K.
    Rawle FC, Tollefson AE, Wold WS, Gooding LR.
    J Immunol; 1989 Sep 15; 143(6):2031-7. PubMed ID: 2789254
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
    Poller W, Schneider-Rasp S, Liebert U, Merklein F, Thalheimer P, Haack A, Schwaab R, Schmitt C, Brackmann HH.
    Gene Ther; 1996 Jun 15; 3(6):521-30. PubMed ID: 8789802
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
    Robinson M, Ge Y, Ko D, Yendluri S, Laflamme G, Hawkins L, Jooss K.
    Cancer Gene Ther; 2008 Jan 15; 15(1):9-17. PubMed ID: 17853920
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice.
    Toth K, Doronin K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS.
    Virus Res; 2005 Mar 15; 108(1-2):149-59. PubMed ID: 15681065
    [Abstract] [Full Text] [Related]

  • 16. Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells.
    Hibma MH, Real NC, Wiles A, Dobson-Le D, Dix BR, Wynford-Thomas D, Braithwaite AW, Royds JA.
    Virus Res; 2009 Oct 15; 145(1):112-20. PubMed ID: 19576936
    [Abstract] [Full Text] [Related]

  • 17. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M, Hakkarainen T, Bauerschmitz GJ, Särkioja M, Desmond RA, Kanerva A, Hemminki A.
    Gene Ther; 2007 Oct 15; 14(19):1380-8. PubMed ID: 17611584
    [Abstract] [Full Text] [Related]

  • 18. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region.
    Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M.
    Cancer Res; 2005 Nov 15; 65(22):10154-8. PubMed ID: 16287998
    [Abstract] [Full Text] [Related]

  • 19. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.
    Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P.
    Nat Biotechnol; 2001 Nov 15; 19(11):1035-41. PubMed ID: 11689848
    [Abstract] [Full Text] [Related]

  • 20. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.
    Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R.
    Mol Ther; 2009 Apr 15; 17(4):614-22. PubMed ID: 19223865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.